search
Back to results

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Primary Purpose

Respiratory Syncytial Virus Infections

Status
Withdrawn
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
RSV vaccine (GSK3003891A) formulation 1
RSV vaccine (GSK3003891A) formulation 2
RSV vaccine (GSK3003891A) formulation 3
Placebo (Formulation buffer S9b)
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Respiratory Syncytial Virus Infections focused on measuring Maternal immunization, Immunogenicity, Vaccines, Safety, Reactogenicity, Respiratory Syncytial Virus

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written informed consent for study participation of the mother obtained from the mother or the mother and father, as applicable by local law, prior to performance of any study specific procedure.
  • Written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or legally acceptable representative [LAR] prior to performance of any study specific procedure.
  • Subjects between, and including, 18 and 40 years of age at the time of the first study visit.
  • Pregnant females > 24 weeks of gestation at the time of screening and at 28 0/7 to 33 6/7 weeks of gestation at the time of vaccination, as established by ultrasound examination and last menstrual period date.
  • Healthy pregnant females as established by medical history and clinical examination before entering into the study.
  • Pregnant females not at high risk for complications, as determined by the obstetrical risk assessment form.
  • No significant foetal findings observed during a second or third trimester ultrasound.
  • Subjects who are willing to provide cord blood.
  • Subjects who do not plan to give their child for adoption or place the child in care.

Inclusion Criteria infants:

• Re-signed written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or LAR.

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before vaccination , or planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before vaccination and ending at delivery with the exception of seasonal influenza vaccine and diphtheria, tetanus, pertussis/tetanus, diphtheria, pertussis [dTpa/Tdap] vaccine as part of standard of care which may be administered ≥ 15 days before or after study vaccination.
  • Chronic administration of systemic immunosuppressants or other immune-modifying drugs, as well as administration of long-acting immune-modifying drugs during the period starting 6 months prior to study vaccination, or planned administration up to delivery. Topical steroids are allowed. Inhaled steroids are allowed up to the limit of ≤500 µg/day for beclomethasone or fluticasone, or ≤ 800 µg/day for budesonide.
  • Administration of immunoglobulins (with the exception of prophylactic anti-Rh0D immune globulin) and/or any blood products during the period starting 3 months before study vaccination or planned administration during the study period.
  • Previous experimental vaccination against RSV.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Low lying placenta during the current pregnancy, unless there is documented sonographic evidence that the placenta has moved up prior to enrolment.
  • Any abnormal finding observed in nuchal translucency scan, serum testing and any other prenatal tests, if conducted.
  • Incompetent cervix or cerclage during the current pregnancy.
  • Having received medical treatment for suspected preterm delivery during the current pregnancy.
  • Prior preterm delivery or having ongoing intervention in current pregnancy to prevent preterm delivery.
  • Prior stillbirth or neonatal death, or ≥ 2 spontaneous abortions.
  • Personal history of major congenital anomalies or early onset of eclampsia/pre-eclampsia in previous pregnancy.
  • 1st degree relatives family history of major congenital anomalies and/ or hereditary immunodeficiency.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Hemodynamically significant cardiac disorders.
  • Gestational diabetes as determined by glucose challenge/tolerance test conducted after 20 weeks of gestation or as per local recommendations of the country, requiring intervention other than diet for control. In countries where glucose challenge/tolerance testing is not routinely performed in all pregnant women, should the screening urinalysis test show presence of glucose in urine, a glucose challenge/tolerance test should be performed and results should be available prior to enrolment, in order to exclude gestational diabetes prior to subject receiving the study vaccine.
  • History of gestational diabetes in previous pregnancy(ies).
  • Hypertension during the current pregnancy as defined below or if any antihypertensive medication is being provided, or history of hypertension requiring antihypertensive medication:

Hypertension during current pregnancy is defined as:

  • a blood pressure systolic > 140 and/or diastolic 90 mmHg, documented in at least 2 separate measurements .

    • Current obstetric cholestasis or history of obstetric cholestasis.
    • Asthma and/or chronic obstructive pulmonary disease [COPD] if the subject is receiving treatment with chronic systemic glucocorticoids at any dose or inhaled glucocorticoids > 500 µg/day of beclomethasone or fluticasone, or > 800 µg/day of budesonide.
    • Significant neuro-psychiatric illness deemed likely to interfere with protocol compliance, safety reporting or receipt of pre-natal care, or requiring treatment with psychotropic drugs.
    • Diagnosed with Zika virus infection or suspected to have or have had Zika virus infection during the current pregnancy.
    • Known HIV infection, as assessed by local standard of care serologic tests conducted during the current pregnancy and prior to enrolment.
    • Known or suspected Hepatitis B virus [HBV] or Hepatitis C virus [HCV] infection.
    • Known infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Rubella, cytomegalovirus [CMV] or primary Herpes Simplex.
    • Known foetal anomalies in the current pregnancy.
    • Any clinically significant haematological and/or biochemical laboratory abnormality.
  • Subjects with haematological/ biochemical values out of normal range which are expected to be temporary may be re-screened at a later date within the allowed time interval.

    • Acute disease and/or fever within 3 days prior to enrolment .

  • Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route.
  • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
  • For subjects with acute disease and/ or fever at the time of enrolment, Visit 1 may be scheduled at a later date within the allowed time interval and gestational age.

    • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
    • Hypersensitivity to latex.
    • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
    • History of drug or alcohol abuse within the past 2 years.
    • Any condition which, in the investigator's opinion, would increase the risks of study participation to the unborn infant.
    • Planned move to a location that will prohibit participating in the trial until study end.

Exclusion Criteria infants:

• Any condition which, in the investigator's opinion, would increase the risks of study participation to the infant.

Sites / Locations

  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

No Intervention

No Intervention

No Intervention

No Intervention

Arm Label

GSK3003891A vaccine formulation 1 mother Group

GSK3003891A vaccine formulation 2 mother Group

GSK3003891A vaccine formulation 3 mother Group

Control group

GSK3003891A vaccine formulation 1 infant Group

GSK3003891A vaccine formulation 2 infant Group

GSK3003891A vaccine formulation 3 infant Group

Control infant Group

Arm Description

Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.

Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.

Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.

Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.

Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine

Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine

Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine

Infants born to mothers who received a single placebo injection

Outcomes

Primary Outcome Measures

Number of subjects with solicited local adverse events (AEs)
Assessed solicited local symptoms are pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevents normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Number of subjects with solicited general AEs
Assessed solicited general symptoms are fatigue, fever [defined as oral/axillary/tympanic route temperature equal to or above 37.5 degrees Celsius (°C) or ≥ 38 °C for rectal route], gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevents normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination
Number of subjects with unsolicited AEs
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevents normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Number of subjects with haematological abnormalities
Haematological laboratory abnormalities include haemoglobin level, white blood cell count [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.
Number of subjects with haematological abnormalities
Haematological laboratory abnormalities include haemoglobin level, white blood cell count [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.
Number of subjects with biochemical abnormalities
Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.
Number of subjects with biochemical abnormalities
Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.
Number of subjects with any serious adverse events (SAEs)
SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Number of infant subjects with any SAEs
SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Number of subjects with pregnancy outcomes
Pregnancy outcomes include live birth with no congenital anomalies, live birth with congenital anomalies, foetal death/still birth with no congenital anomalies, foetal death/still birth with congenital anomalies, elective/therapeutic termination with no congenital anomalies and elective/therapeutic termination with congenital anomalies.
Number of subjects with pregnancy-related AEs of specific interest
Pregnancy-related adverse events of specific interest include: gestational diabetes, gestational liver disease (including obstetric cholestasis and acute fatty liver of pregnancy), chorioamnionitis, labour protraction and arrest disorders, maternal sepsis, pregnancy-related hypertension, preterm premature rupture of membranes, premature labour, intrauterine growth restriction/poor foetal growth, pre-eclampsia and eclampsia, vaginal or intrauterine haemorrhage, medical conditions necessitating early delivery (induced labour or urgent C-section) (placenta abruption, uterine infection, oligohydramnios, etc), maternal death.
Number of infant subjects with AEs of specific interest
Infant-related AEs of specific interest include preterm birth, neonatal death, low birth weight and/or small for gestational age, neonatal sepsis, foetal/perinatal distress or asphyxia, failure to thrive/growth deficiency, congenital anomalies and neurodevelopmental delay.

Secondary Outcome Measures

Number of infant subjects with SAEs
SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Number of infant subjects with AEs potentially related to maternal vaccination
Related infant AEs = AEs occurring in the infant assessed by the investigator as potentially related to the vaccination of the mother.
Number of infant subjects with neuro-developmental delays
Infant subjects with Ages and Stages Questionnaires version 3 (ASQ-3) scores in the grey and black zones for any of the 5 developmental areas or domains (communication, gross motor skills, fine motor skills, problem solving and personal-social) : Grey zone (i.e. Monitoring zone) score means that the child's score falls ≥ 1 but <2 standard deviations below the mean score in any developmental area. Black zone (i.e. Referral zone) score means that the child's score falls below the cut-off (i.e. 2 standard deviations below the mean score) in any developmental area. Infant subjects scoring in the black zone in any of the 5 domains of the ASQ-3 will be referred for formal neurological evaluation
Number of infant subjects referred for formal neurological evaluation
Neuro-developmental formal evaluation will be performed, for infants with ASQ3 black zone scores, using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.
Number of infant subjects with confirmed developmental delay
Infants confirmed as having neuro-developmental delay following formal evaluation using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.
Neutralizing antibody titres against RSV-A, for all vaccinated mothers
Titres will be expressed as geometric mean titres (GMTs)
Neutralizing antibody titres against RSV-B, for all vaccinated mothers
Titres will be expressed as geometric mean titres (GMTs)
Palivizumab competing antibody (PCA) concentrations, for all vaccinated mothers.
Concentrations will be expressed as geometric mean concentrations (GMCs)
Neutralizing antibody titres against RSV-A, for all infants born to vaccinated mothers
Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
Neutralizing antibody titres against RSV-B, for all infants born to vaccinated mothers
Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
PCA concentrations, for all infants born to vaccinated mothers
Concentrations will be expressed as geometric mean concentrations (GMCs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
Number of infant subjects with lower respiratory tract infection (LRTI), severe LRTI and respiratory tract infection (RTI) with parental concern (according to the case definitions) associated with a respiratory syncytial virus (RSV) infection
Occurrence of RSV-LRTI, severe RSV-LRTI, RSV-RTI with parental concern
Number of subjects (vaccinated mothers) with medically-attended (MA) RTI associated with an RSV infection
Occurrence of RSV associated MA-RTI. A MA-RTI is defined as a visit of the mother to a health care professional for any respiratory symptom, including cough, sputum production and difficulty breathing

Full Information

First Posted
June 15, 2017
Last Updated
October 12, 2018
Sponsor
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT03191383
Brief Title
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
Official Title
An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Withdrawn
Why Stopped
Study was canceled due to instability of the PreF antigen during manufacturing. No safety concern has been identified in past or ongoing studies.
Study Start Date
July 11, 2017 (Actual)
Primary Completion Date
July 14, 2017 (Actual)
Study Completion Date
July 14, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Syncytial Virus Infections
Keywords
Maternal immunization, Immunogenicity, Vaccines, Safety, Reactogenicity, Respiratory Syncytial Virus

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GSK3003891A vaccine formulation 1 mother Group
Arm Type
Experimental
Arm Description
Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
Arm Title
GSK3003891A vaccine formulation 2 mother Group
Arm Type
Experimental
Arm Description
Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
Arm Title
GSK3003891A vaccine formulation 3 mother Group
Arm Type
Experimental
Arm Description
Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
Arm Title
GSK3003891A vaccine formulation 1 infant Group
Arm Type
No Intervention
Arm Description
Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
Arm Title
GSK3003891A vaccine formulation 2 infant Group
Arm Type
No Intervention
Arm Description
Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
Arm Title
GSK3003891A vaccine formulation 3 infant Group
Arm Type
No Intervention
Arm Description
Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
Arm Title
Control infant Group
Arm Type
No Intervention
Arm Description
Infants born to mothers who received a single placebo injection
Intervention Type
Biological
Intervention Name(s)
RSV vaccine (GSK3003891A) formulation 1
Intervention Description
Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Intervention Type
Biological
Intervention Name(s)
RSV vaccine (GSK3003891A) formulation 2
Intervention Description
Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Intervention Type
Biological
Intervention Name(s)
RSV vaccine (GSK3003891A) formulation 3
Intervention Description
Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Intervention Type
Drug
Intervention Name(s)
Placebo (Formulation buffer S9b)
Intervention Description
Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Primary Outcome Measure Information:
Title
Number of subjects with solicited local adverse events (AEs)
Description
Assessed solicited local symptoms are pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevents normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time Frame
During a 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days)
Title
Number of subjects with solicited general AEs
Description
Assessed solicited general symptoms are fatigue, fever [defined as oral/axillary/tympanic route temperature equal to or above 37.5 degrees Celsius (°C) or ≥ 38 °C for rectal route], gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevents normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination
Time Frame
During the 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days)
Title
Number of subjects with unsolicited AEs
Description
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevents normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time Frame
During a 30-day follow-up period after vaccination (i.e. the day of vaccination and 29 subsequent days)
Title
Number of subjects with haematological abnormalities
Description
Haematological laboratory abnormalities include haemoglobin level, white blood cell count [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.
Time Frame
At Day 0
Title
Number of subjects with haematological abnormalities
Description
Haematological laboratory abnormalities include haemoglobin level, white blood cell count [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.
Time Frame
At Day 7
Title
Number of subjects with biochemical abnormalities
Description
Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.
Time Frame
At Day 0
Title
Number of subjects with biochemical abnormalities
Description
Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.
Time Frame
At Day 7
Title
Number of subjects with any serious adverse events (SAEs)
Description
SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time Frame
From study start (Day 0) up to 6 months after delivery
Title
Number of infant subjects with any SAEs
Description
SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time Frame
From birth up to 6 months after birth
Title
Number of subjects with pregnancy outcomes
Description
Pregnancy outcomes include live birth with no congenital anomalies, live birth with congenital anomalies, foetal death/still birth with no congenital anomalies, foetal death/still birth with congenital anomalies, elective/therapeutic termination with no congenital anomalies and elective/therapeutic termination with congenital anomalies.
Time Frame
From study start (Day 0) up to delivery
Title
Number of subjects with pregnancy-related AEs of specific interest
Description
Pregnancy-related adverse events of specific interest include: gestational diabetes, gestational liver disease (including obstetric cholestasis and acute fatty liver of pregnancy), chorioamnionitis, labour protraction and arrest disorders, maternal sepsis, pregnancy-related hypertension, preterm premature rupture of membranes, premature labour, intrauterine growth restriction/poor foetal growth, pre-eclampsia and eclampsia, vaginal or intrauterine haemorrhage, medical conditions necessitating early delivery (induced labour or urgent C-section) (placenta abruption, uterine infection, oligohydramnios, etc), maternal death.
Time Frame
From study start (Day 0) up to delivery
Title
Number of infant subjects with AEs of specific interest
Description
Infant-related AEs of specific interest include preterm birth, neonatal death, low birth weight and/or small for gestational age, neonatal sepsis, foetal/perinatal distress or asphyxia, failure to thrive/growth deficiency, congenital anomalies and neurodevelopmental delay.
Time Frame
From birth up to 6 months after birth
Secondary Outcome Measure Information:
Title
Number of infant subjects with SAEs
Description
SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time Frame
From birth and up to study end (Year 2)
Title
Number of infant subjects with AEs potentially related to maternal vaccination
Description
Related infant AEs = AEs occurring in the infant assessed by the investigator as potentially related to the vaccination of the mother.
Time Frame
From birth up to study end (Year 2)
Title
Number of infant subjects with neuro-developmental delays
Description
Infant subjects with Ages and Stages Questionnaires version 3 (ASQ-3) scores in the grey and black zones for any of the 5 developmental areas or domains (communication, gross motor skills, fine motor skills, problem solving and personal-social) : Grey zone (i.e. Monitoring zone) score means that the child's score falls ≥ 1 but <2 standard deviations below the mean score in any developmental area. Black zone (i.e. Referral zone) score means that the child's score falls below the cut-off (i.e. 2 standard deviations below the mean score) in any developmental area. Infant subjects scoring in the black zone in any of the 5 domains of the ASQ-3 will be referred for formal neurological evaluation
Time Frame
At Year 1 and Year 2
Title
Number of infant subjects referred for formal neurological evaluation
Description
Neuro-developmental formal evaluation will be performed, for infants with ASQ3 black zone scores, using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.
Time Frame
At Year 1 and Year 2
Title
Number of infant subjects with confirmed developmental delay
Description
Infants confirmed as having neuro-developmental delay following formal evaluation using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.
Time Frame
At Year 1 and Year 2
Title
Neutralizing antibody titres against RSV-A, for all vaccinated mothers
Description
Titres will be expressed as geometric mean titres (GMTs)
Time Frame
At pre-vaccination (Day 0), Day 30 and Day 60 post vaccination and at delivery
Title
Neutralizing antibody titres against RSV-B, for all vaccinated mothers
Description
Titres will be expressed as geometric mean titres (GMTs)
Time Frame
At pre-vaccination (Day 0), Day 30 and Day 60 post vaccination and at delivery
Title
Palivizumab competing antibody (PCA) concentrations, for all vaccinated mothers.
Description
Concentrations will be expressed as geometric mean concentrations (GMCs)
Time Frame
At pre-vaccination (Day 0), Day 30 and Day 60 post-vaccination and at delivery
Title
Neutralizing antibody titres against RSV-A, for all infants born to vaccinated mothers
Description
Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
Time Frame
At birth, at Month 3 and at Month 6
Title
Neutralizing antibody titres against RSV-B, for all infants born to vaccinated mothers
Description
Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
Time Frame
At birth, at Month 3 and at Month 6
Title
PCA concentrations, for all infants born to vaccinated mothers
Description
Concentrations will be expressed as geometric mean concentrations (GMCs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
Time Frame
At birth, at Month 3 and at Month 6
Title
Number of infant subjects with lower respiratory tract infection (LRTI), severe LRTI and respiratory tract infection (RTI) with parental concern (according to the case definitions) associated with a respiratory syncytial virus (RSV) infection
Description
Occurrence of RSV-LRTI, severe RSV-LRTI, RSV-RTI with parental concern
Time Frame
From birth up to study end (Year 2)
Title
Number of subjects (vaccinated mothers) with medically-attended (MA) RTI associated with an RSV infection
Description
Occurrence of RSV associated MA-RTI. A MA-RTI is defined as a visit of the mother to a health care professional for any respiratory symptom, including cough, sputum production and difficulty breathing
Time Frame
From Day 0 up to Month 6 post delivery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. Written informed consent for study participation of the mother obtained from the mother or the mother and father, as applicable by local law, prior to performance of any study specific procedure. Written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or legally acceptable representative [LAR] prior to performance of any study specific procedure. Subjects between, and including, 18 and 40 years of age at the time of the first study visit. Pregnant females > 24 weeks of gestation at the time of screening and at 28 0/7 to 33 6/7 weeks of gestation at the time of vaccination, as established by ultrasound examination and last menstrual period date. Healthy pregnant females as established by medical history and clinical examination before entering into the study. Pregnant females not at high risk for complications, as determined by the obstetrical risk assessment form. No significant foetal findings observed during a second or third trimester ultrasound. Subjects who are willing to provide cord blood. Subjects who do not plan to give their child for adoption or place the child in care. Inclusion Criteria infants: • Re-signed written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or LAR. Exclusion Criteria: Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before vaccination , or planned use during the study period. Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before vaccination and ending at delivery with the exception of seasonal influenza vaccine and diphtheria, tetanus, pertussis/tetanus, diphtheria, pertussis [dTpa/Tdap] vaccine as part of standard of care which may be administered ≥ 15 days before or after study vaccination. Chronic administration of systemic immunosuppressants or other immune-modifying drugs, as well as administration of long-acting immune-modifying drugs during the period starting 6 months prior to study vaccination, or planned administration up to delivery. Topical steroids are allowed. Inhaled steroids are allowed up to the limit of ≤500 µg/day for beclomethasone or fluticasone, or ≤ 800 µg/day for budesonide. Administration of immunoglobulins (with the exception of prophylactic anti-Rh0D immune globulin) and/or any blood products during the period starting 3 months before study vaccination or planned administration during the study period. Previous experimental vaccination against RSV. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. Low lying placenta during the current pregnancy, unless there is documented sonographic evidence that the placenta has moved up prior to enrolment. Any abnormal finding observed in nuchal translucency scan, serum testing and any other prenatal tests, if conducted. Incompetent cervix or cerclage during the current pregnancy. Having received medical treatment for suspected preterm delivery during the current pregnancy. Prior preterm delivery or having ongoing intervention in current pregnancy to prevent preterm delivery. Prior stillbirth or neonatal death, or ≥ 2 spontaneous abortions. Personal history of major congenital anomalies or early onset of eclampsia/pre-eclampsia in previous pregnancy. 1st degree relatives family history of major congenital anomalies and/ or hereditary immunodeficiency. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. Hemodynamically significant cardiac disorders. Gestational diabetes as determined by glucose challenge/tolerance test conducted after 20 weeks of gestation or as per local recommendations of the country, requiring intervention other than diet for control. In countries where glucose challenge/tolerance testing is not routinely performed in all pregnant women, should the screening urinalysis test show presence of glucose in urine, a glucose challenge/tolerance test should be performed and results should be available prior to enrolment, in order to exclude gestational diabetes prior to subject receiving the study vaccine. History of gestational diabetes in previous pregnancy(ies). Hypertension during the current pregnancy as defined below or if any antihypertensive medication is being provided, or history of hypertension requiring antihypertensive medication: Hypertension during current pregnancy is defined as: a blood pressure systolic > 140 and/or diastolic 90 mmHg, documented in at least 2 separate measurements . Current obstetric cholestasis or history of obstetric cholestasis. Asthma and/or chronic obstructive pulmonary disease [COPD] if the subject is receiving treatment with chronic systemic glucocorticoids at any dose or inhaled glucocorticoids > 500 µg/day of beclomethasone or fluticasone, or > 800 µg/day of budesonide. Significant neuro-psychiatric illness deemed likely to interfere with protocol compliance, safety reporting or receipt of pre-natal care, or requiring treatment with psychotropic drugs. Diagnosed with Zika virus infection or suspected to have or have had Zika virus infection during the current pregnancy. Known HIV infection, as assessed by local standard of care serologic tests conducted during the current pregnancy and prior to enrolment. Known or suspected Hepatitis B virus [HBV] or Hepatitis C virus [HCV] infection. Known infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Rubella, cytomegalovirus [CMV] or primary Herpes Simplex. Known foetal anomalies in the current pregnancy. Any clinically significant haematological and/or biochemical laboratory abnormality. Subjects with haematological/ biochemical values out of normal range which are expected to be temporary may be re-screened at a later date within the allowed time interval. • Acute disease and/or fever within 3 days prior to enrolment . Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route. Subjects with a minor illness without fever may be enrolled at the discretion of the investigator. For subjects with acute disease and/ or fever at the time of enrolment, Visit 1 may be scheduled at a later date within the allowed time interval and gestational age. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. Hypersensitivity to latex. Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe. History of drug or alcohol abuse within the past 2 years. Any condition which, in the investigator's opinion, would increase the risks of study participation to the unborn infant. Planned move to a location that will prohibit participating in the trial until study end. Exclusion Criteria infants: • Any condition which, in the investigator's opinion, would increase the risks of study participation to the infant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Newton
State/Province
Kansas
ZIP/Postal Code
67114
Country
United States
Facility Name
GSK Investigational Site
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
Facility Name
GSK Investigational Site
City
Ellensburg
State/Province
Washington
ZIP/Postal Code
98926
Country
United States
Facility Name
GSK Investigational Site
City
Oulu
ZIP/Postal Code
90220
Country
Finland
Facility Name
GSK Investigational Site
City
Seinajoki
ZIP/Postal Code
60100
Country
Finland
Facility Name
GSK Investigational Site
City
Aravaca
ZIP/Postal Code
28023
Country
Spain
Facility Name
GSK Investigational Site
City
Burgos
ZIP/Postal Code
09006
Country
Spain
Facility Name
GSK Investigational Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
GSK Investigational Site
City
Majadahonda (Madrid)
ZIP/Postal Code
28222
Country
Spain
Facility Name
GSK Investigational Site
City
Santiago de Compostela
ZIP/Postal Code
15706
Country
Spain
Facility Name
GSK Investigational Site
City
Santiago
ZIP/Postal Code
15705
Country
Spain
Facility Name
GSK Investigational Site
City
Sevilla
ZIP/Postal Code
41014
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Patient-level data for this study will be made available through https://www.clinicalstudydatarequest.com/ following the timelines and process described on this site.

Learn more about this trial

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

We'll reach out to this number within 24 hrs